Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Dr. Mona Ashiya, a director of Shattuck Labs, Inc. (STTK), was granted a stock option on 08/28/2025 allowing purchase of 66,300 shares of common stock at a $0.99 exercise price. The option vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, is exercisable beginning on those vesting dates, and expires on August 28, 2035. The Form 4 reports 66,300 derivative securities beneficially owned following the transaction, filed by one reporting person and signed by an attorney-in-fact on 09/02/2025. An agreement requires the Reporting Person to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for allocation to OrbiMed Private Investments IX, LP.
Shattuck Labs director Dr. Daniel G. Baker received a stock option award for 66,300 shares of common stock with a $0.99 exercise price on 08/28/2025. The option vests in three equal annual installments beginning on the grant date and is exercisable through 08/28/2035, subject to continued service. The Form 4 was filed on 09/02/2025 and signed by an attorney-in-fact. The disclosure shows an executive compensation action that increases potential common shares outstanding if exercised and ties the director's future economic incentive to the company's stock performance.
Shattuck Labs, Inc. director Dr. Daniel G. Baker has filed an initial insider ownership report on Form 3 for Shattuck Labs, Inc. (STTK). The filing identifies him as a director and indicates that the form is filed by one reporting person. In the remarks section, it explicitly states that no securities are beneficially owned, meaning Dr. Baker reported no direct or indirect ownership of Shattuck Labs securities as of the event date.
Shattuck Labs director Dr. Mona Ashiya filed an initial ownership report on Form 3 for Shattuck Labs, Inc. (STTK). The filing states in the remarks section that no securities are beneficially owned, meaning the reporting person did not report any direct or indirect ownership of Shattuck Labs stock or derivative securities as of the event date.
Shattuck Labs insider Stephen Stout, the company's General Counsel and Corporate Secretary, acquired 12,805 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025. The combined price per share and warrant was $0.8677. The warrants allow purchase of up to 12,805 additional shares at an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 clinical trial data and the design of planned Phase 2 trial(s). Following the transaction, Stout beneficially owns 86,275 shares of common stock.
Shattuck Labs CFO Andrew R. Neill purchased 64,027 shares and received 64,027 accompanying warrants in a private placement that closed on August 25, 2025. The combined price paid for each share plus warrant was $0.8677, and the warrants have an exercise price of $1.0846. After the transaction the reporting person beneficially owned 237,473 shares. The warrants are exercisable any time after issuance until 30 days following public disclosure of specified Phase 1 clinical trial data and the planned Phase 2 design for SL-325.
Insider purchase reported: Clay B. Siegall, a director of Shattuck Labs, Inc. (STTK), participated in a private placement that closed on August 25, 2025, acquiring 128,054 shares of common stock and accompanying warrants to buy up to 128,054 additional shares. The combined price for one share plus its accompanying warrant was $0.8677. The warrants have an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 SL-325 trial data and the planned Phase 2 design.
Shattuck Labs insider purchase reported. The company's Chief Technical Officer, Abhinav A. Shukla, acquired 5,122 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025 at a combined purchase price of $0.8677 per share with accompanying warrant. The filing also notes Shukla beneficially owns 81,258 shares after the transaction, which includes 600 shares purchased via the 2020 Employee Stock Purchase Plan on February 15, 2025 and 2,000 shares under the ESPP on August 15, 2025. The warrants cover 5,122 shares exercisable upon public disclosure of Phase 1 clinical trial data and planned Phase 2 design.
Insider purchase and warrant grant reported for Shattuck Labs (STTK). Taylor Schreiber, the company’s Chief Executive Officer and a director, participated in a private placement that closed on August 25, 2025, acquiring 25,610 shares of common stock at $0.8677 per share and receiving accompanying warrants to buy up to 25,610 shares. After the transaction Schreiber directly owns 96,612 shares. Schreiber also holds an indirect interest of 2,610,750 shares through Houghton Capital Holdings, LLC. The warrants are exercisable until the 30th day after the issuer publicly announces specific Phase 1 clinical trial data and planned Phase 2 design.
Redmile Group and affiliated funds acquired warrants and pre-funded warrants in Shattuck Labs' private placement (PIPE) closed August 25, 2025, increasing their reported economic exposure to 6,379,095 shares of common stock, representing 9.99% of the outstanding class on the stated calculation basis.
The Redmile Funds paid approximately $3,555,190 in aggregate to purchase Pre-Funded Warrants and Common Warrants at a combined purchase price of $0.8676, with RBI II contributing approximately $1,777,211. The filing details registration rights for resale of Common Stock issuable on exercise and describes a Beneficial Ownership Blocker that limits actual exercises to prevent ownership above 9.99%.